SCHEMBL22225552

SCHEMBL22225552

CCC[C@H]1CCCOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8462652 1.00
SCHEMBL4411644 1.00
SCHEMBL13069521 0.93 CYP1A2 (0.41)
SCHEMBL3614853 0.93 CYP1A2 (0.41)
SCHEMBL17308764 0.87 CYP1A2 (0.56)
SCHEMBL14864952 0.87 CYP1A2 (0.56)
SCHEMBL14117939 0.86
SCHEMBL18660981 0.86
SCHEMBL6032197 0.86
SCHEMBL4910497 0.85 CYP1A2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3858832-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-08-04 EP disclosed
US-20200222393-A1 COMBINATION PRODUCT OF BCL-2 INHIBITOR OR BCL-2/BCL-XL DUAL INHIBITOR AND BTK INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2020-07-16 US disclosed